Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PBF 999 |
| Synonyms | |
| Therapy Description |
PBF 999 inhibits both adenosine A2A receptor (A2AR) and phosphodiesterase 10A (PDE-10A), which potentially leads to activation of immune response and inhibition of tumor cell growth (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PBF 999 | PBF-999|PBF999 | Adenosine Targeting 24 | PBF 999 inhibits both adenosine A2A receptor (A2AR) and phosphodiesterase 10A (PDE-10A), which potentially leads to activation of immune response and inhibition of tumor cell growth (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03786484 | Phase I | PBF 999 | Study of PBF-999 in Solid Tumour Advanced Cancer | Completed | ESP | 0 |